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Abstract
Background: ALM solution, a combination of adenosine, lidocaine and Mg2+, is an emerging small volume therapy
that has been shown to prevent and correct coagulopathy and surgery-related inflammation in preclinical models,
though its application in orthopaedic surgery is yet to be demonstrated. The effect of ALM solution on
chondrocytes is unknown. The aim of this preliminary study was to investigate the effect of ALM solution on
viability and inflammatory responses of chondrogenically-differentiated human bone marrow-derived mesenchymal
stem cells (chondro-MSC), in vitro.
Methods: Chondro-MSC were exposed to media only, saline (0.9% NaCl or 1.3% NaCl) only, or saline containing
ALM (1 mM adenosine, 3 mM lidocaine, 2.5 mM Mg2+) or tranexamic acid (TXA, 100 mg/ml) for 1 or 4 h. Responses
to ALM solutions containing higher lidocaine concentrations were also compared. Chondrocyte viability was
determined using WST-8 colorimetric assays and inflammatory cytokine (TNF-α, IL-1β, IL-8) and matrix
metalloproteinases (MMP-3, MMP-12, MMP-13) concentrations using multiplex bead arrays.
Results: The viability of chondro-MSC was significantly greater after 1 h treatment with ALM compared to saline
(96.2 ± 7.9 versus 75.6 ± 7.3%). Extension of exposure times to 4 h had no significant adverse effect on cell viability
after treatment with ALM (1 h, 85.4 ± 5.6 v 4 h, 74.0 ± 15.2%). Cytotoxicity was evident following exposure to
solutions containing lidocaine concentrations greater than 30 mM. There were no significant differences in viability
(80 ± 5.4 v 57.3 ± 16.2%) or secretion of IL-8 (60 ± 20 v 160 ± 50 pg/ml), MMP-3 (0.95 ± 0.6 v 3.4 ± 1.6 ng/ml), and
MMP-13 (4.2 ± 2.4 v 9.2 ± 4.3 ng/ml) in chondro-MSC exposed to saline, ALM or TXA.
Conclusions: Short-term, in vitro exposure to clinically-relevant concentrations of ALM solution had no adverse
inflammatory or chondrotoxic effects on human chondro-MSC, with responses comparable to saline and TXA.
These findings provide support for continued evaluation of ALM solution as a possible therapeutic to improve
outcomes following orthopaedic procedures.
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Background
An ageing population and rise in prevalence of comorbid
chronic disease is projected to drive a continued global in-
crease in demand for elective arthroscopy and arthroplasty
procedures (Inacio et al. 2017a, b, Holtedahl et al. 2018).
As with any surgery, there are a number of potential com-
plications following orthopaedic surgical procedures
including local bleeding, coagulopathy, inflammation and
tissue trauma (Cheuy et al. 2017, Friberger Pajalic et al.
2018). While inflammation and immune modulation are
essential for tissue repair, sustained or overexpression of
these responses can lead to further bleeding, joint damage,
infection and arthrofibrosis (Eming et al. 2007, Dobson
2015, Järvinen and Guyatt 2016, Werthel et al. 2017).
The anti-fibrinolytic tranexamic acid (TXA) has become
increasingly popular in orthopaedic procedures to
improve visualization and reduce some of these complica-
tions (Karaaslan et al. 2015, Demos et al. 2017, Abdel et
al. 2018). However, debate continues regarding the effect
of TXA on articular cartilage and post-operative
inflammation (Jang et al. 2014, Goyal et al. 2017, Filling-
ham et al. 2018, Grant et al. 2018, Moskal and Capps
2018, Parker et al. 2018). A combination of adenosine,
lidocaine and Mg2+ (ALM solution) is an emerging small
volume therapy that has been shown to prevent and cor-
rect coagulopathy and surgery-related inflammation, and
reduce the trauma of surgery in several preclinical models
(Dobson and Letson 2016). In contrast to TXA, which
acts as a downstream anti-fibrinolytic (Reed and Woolley
2015, Dobson et al. 2018), ALM appears to correct coagu-
lopathy upstream at the thrombomodulin complex located
on the endothelium (Dobson et al. 2015, Dobson and Let-
son 2016). In addition, ALM has been shown to be a
potent anti-inflammatory following hemorrhagic shock,
traumatic brain injury, abdominal surgery and polymicro-
bial sepsis (Granfeldt et al. 2014, Griffin et al. 2014, Letson
and Dobson 2015, Griffin et al. 2016, Davenport et al.
2017, Letson and Dobson 2017a, b Letson and Dobson
2018a, b). The application of ALM solution in orthopaedic
surgical procedures is yet to be described. However, based
on preclinical models of major surgery (Dobson and
Letson 2016, Davenport et al. 2017), ALM solution
has the potential to correct coagulopathy and reduce
tissue-damaging inflammatory responses following
joint injury and during orthopaedic procedures. As a
precursor to evaluating ALM solution in orthopaedic
models, preliminary in vitro studies are necessary to
determine if clinically-relevant concentrations of ALM
solution exert potentially adverse effects on human
chondrocytes. Due to difficulties associated with iso-
lating and maintaining primary human chondrocytes
cultures at sufficient cell densities for in vitro charac-
terisation assays, chondrogenically-differentiated hu-
man bone marrow-derived mesenchymal stem cells
(chondro-MSC) were used as a substitute for these
proof-of-concept studies. Our aim was to investigate
the effect of ALM solution on viability and inflamma-
tory responses of chondro-MSC, in vitro. We
hypothesised that ALM solution would show no cyto-
toxic or stimulatory effect on chondro-MSC, and
would be comparable to saline and TXA.
Methods
Approvals
Informed consent was obtained prospectively from all
participants, and the study was approved by the Insti-
tutional Human Research Ethics Committee (HREC/
15/QTHS/39). The research undertaken strictly
adhered to the Code of Ethics (Declaration of
Helsinki) of the World Medical Association for trials
involving humans.
Cell isolation, culture conditions and in vitro chrondrogenic
differentiation
Ten patients (8 male, 2 females; age range 20–66 years)
undergoing a bone marrow biopsy procedure as part of
a routine assessment of their remission status for a
haematological condition were recruited to participate in
the study following informed consent. The buffy coat
from an aspirated bone marrow sample (1 ml) was iso-
lated from each patient and washed in HBSS. Nucleated
cells (2 × 107) were plated in 75cm2 culture flasks (T75)
with Expansion media (Dulbecco Modified Eagle
Medium, DMEM + GlutaMAX, Thermo Fisher Scien-
tific, Scoresby, VIC) supplemented with foetal bovine
serum (10%, Sigma-Aldrich, Castle Hill, NSW), hu-
man fibroblast growth factor (2 ng/ml, Miltenyi Bio-
tec, Macquarie Park, NSW), and penicillin/
streptomycin (1%, Thermo Fisher Scientific), and cul-
tured for 24 h at 37 °C in a humidified atmosphere of
5% CO2. Non-adherent cells were removed after 24 h
culture, with further media changes performed three
times a week (Mareschi et al. 2012). To promote an
even distribution of MSC, at day 14 the cells were de-
tached with TrypLE™ Express (Thermo Fisher Scientific),
washed and transferred to new flasks, with secondary
cultures reaching 80–90% confluence within 7 days of
subculture. To minimise any loss of differentiation
potential, MSC were not cultured beyond the second
passage.
In vitro chondrogenesis was performed according to
published protocols (Solchaga et al. 2011). Expanded
MSC were trypsinised, washed and 7.5 × 105 cells trans-
ferred to new T75 flasks. Chondrogenic differentiation
was induced by treatment with STEMPRO™ Chondro-
genesis Differentiation medium (Thermo Fisher Scien-
tific) (Kalamegam et al. 2016). Monolayers were
incubated at 37 °C in 5% CO2 with differentiation media
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changes performed three times a week. After 7 days, the
monolayer was observed microscopically to confirm
chondrocyte morphology. Differentiation was regarded
as > 90% conversion of a spindle-shaped, fibroblastic
MSC morphology to a rounded, polygonal morphology
consistent with chondrocyte monolayers (Fig. 1a, b).
Chondro-MSC were not cultured beyond first passage to
avoid de-differentiation. Following visual confirmation,
chondro-MSC were trypsinised, washed and counted.
Chondro-MSC were transferred to the wells of a 96-well
plate at high cell densities (> 5 × 103) to avoid
de-differentiation and were subsequently used for assess-
ment of viability and cytokine production in response to
ALM and TXA exposure as described below.
Histology
To confirm chondrogenic differentiation of MSC using
the culture conditions described above, 5 × 105 MSC
were placed in the wells of a 24-well Transwell® plate
(Sigma-Aldrich) and differentiation media was added,
with media changes performed three times a week (Mur-
doch et al. 2009). After 21 days, the Transwell membrane
was removed and fixed in 4% paraformaldehyde, proc-
essed histologically and paraffin-embedded sections
stained with hematoxylin and eosin (H&E), toluidine
blue and Picro-Mallory trichrome. Chondrocyte aggrega-
tion and early stages of matrix structural organisation
was in evident histologically. Sections stained with tolui-
dine blue demonstrated the presence of negatively
charged proteoglycans, whilst blue colouration in
trichrome-stained sections confirmed the deposition of a
collagenous matrix between chondrocytes (Fig. 1c, d).
Treatments
Adenosine (A9251), Lidocaine-HCl (L5647), and MgSO4
(M7506) were purchased from Sigma-Aldrich. Chondro-
cytes were incubated 1) in media only (no Tx), 2) saline
(0.9% NaCl or 1.3% NaCl) only, 3) adenosine (1 mM)
alone, lidocaine (3 mM) alone, or Mg2+ (2.5 mM) alone,
and 4) ALM solution combined (adenosine 1 mM, lido-
caine 3 mM, Mg2+ 2.5 mM). Given that 1% (~ 37mM)
and 2% (~ 74mM) lidocaine solutions are known to be
toxic to chondrocytes (Karpie and Chu 2007, Baker et al.
2011), we also examined ALM with 30 mM lidocaine
(AL30M) and 60mM lidocaine (AL60M) as internal
controls. In addition, ALM solution (0.9% saline) was
compared to TXA (100 mg/ml in 0.9% saline, Juno Phar-
maceuticals, South Yarra, VIC). Since intra-articular
doses of 1 to 3 g of TXA in 20 ml saline (50–150 mg/ml)
are used in our institution and by others (Ishida et al.
Fig. 1 Chondrogenic differentiation of human MSC. Cellular morphology changes were evident in human MSC (a) prior to, and (b) following
culture in chondrogenic differentiation media for 7 days, with the transformation of spindle-shaped MSC to rounded, polygonal chondrocytes
(magnification, 10x). Chondrogenic differentiation was confirmed histologically, with chondrocyte aggregation and early structural organisation of
a collagenous matrix evident. Representative formalin-fixed, paraffin-embedded sections of chondro-MSC were stained with (c) toluidine blue to
demonstrate sulphated glycosaminoglycans deposition (white arrow) or (d) Picro-Mallory trichrome stain highlighting deposition of collagen
fibres (black arrowhead) within the extracellular matrix (magnification, 20x)
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2011, Tuttle et al. 2014), a concentration of 100 mg/ml
TXA was selected for comparison to ALM solution in
the current study. Chondro-MSC were exposed to treat-
ments for 1 or 4 h (37 °C, 5% CO2) prior to processing
for assessment of viability or secreted inflammatory
cytokines, chemokines and matrix metalloproteinases
(MMP). Exposure times of 1 and 4 h, were selected to
reflect the mean surgical times associated with arthro-
plasty procedures (Weber et al. 2018). The longer expos-
ure time reflects the 4 h ALM infusion times used in
previous in vivo studies to confer protection in preclin-
ical models of trauma, sepsis and surgery (Griffin et al.
2014, Griffin et al. 2016, Letson and Dobson, 2017a, b).
Viability assay
Chondrocyte viability was assessed using a WST-8 col-
orimetric assay, according to manufacturers’ protocol
(Cell Count Kit-8, Sigma Aldrich). The WST-8 assay
assesses mitochondrial ability to reduce WST-8 into
water-soluble tetrazolium salt. Briefly, chondro-MSC
were enzymatically lifted from flasks and dispensed into
a 96-well plate at 5 × 103 cells/well. After incubation for
24 h to allow attachment, ALM or individual compo-
nents were added to appropriate wells for 1 or 4 h (37 °
C, 5% CO2). After treatment, the medium was removed,
fresh culture media added and plates incubated for a
further 18 h (37 °C, 5% CO2). WST-8 (10 μl) was added
and plates incubated for a further 4 h (37 °C, 5% CO2).
Absorbance was measured at 450 nm, with a reference
of 650 nm using a Multiskan EX microplate reader
(Thermo Fisher Scientific). Cell viability was calculated
using the ratio of the absorbance of treated (saline, ALM
or individual components, TXA) cells to the absorbance
of untreated (culture media only) cells, and data were
expressed as percentages.
Cytokine, chemokine and MMP analysis
In a parallel set of experiments, the secretion of inflam-
matory cytokines, chemokines and MMP from
chondro-MSC was compared in ALM- and TXA-treated
cultures. Briefly, expanded MSC were enzymatically
lifted from flasks and dispensed into a 96-well plate (5 ×
104 cells/well). After overnight incubation, expansion
media was replaced with chondrogenic differentiation
media, and cultures incubated for 7 days with differenti-
ation media changes performed three times. Saline only
(0.9%), ALM, or TXA solutions were added to appropri-
ate wells for 1 h. Recombinant human IL-1β was
purchased from Sigma Aldrich (I9401) and included in
each experiment as a positive control (5 ng/ml; Forsyth
et al. 2005). Chondro-MSC were washed, media replaced
and cells incubated for a further 24 h prior to removal of
cell-free supernatants from untreated and treated wells.
Milliplex® Human Cytokine/Chemokine (HCYTOMAG-60
K, Lot #2929279) and MMP Magnetic Bead Panel 1
(HMMP1MAG-55 K, Lot #10101, Abacus ALS, Meadow-
brook, Queensland) in combination with the Magpix® ana-
lyser (Luminex Corporation, Austin, Texas, USA) were
used to measure levels of interleukin (IL)-8, IL-1β, tumor
necrosis factor alpha (TNF-α), MMP-3, MMP-12 and
MMP-13 in chondro-MSC culture supernatants. Assays
were carried out according to manufacturer’s instructions
with samples measured in duplicate.
Statistics
GraphPad Prism 7 was used for all data analysis. Data
normality was assessed using Shapiro-Wilks test, with
Levene’s test used to determine equality of variances.
Viability between groups were compared using t-tests,
univariant variance analysis (ANOVA, Tukey post-hoc
analysis) or two-way ANOVA (Tukey post-hoc analysis)
where appropriate. MILLIPLEX Analyst 5.1 software
(Luminex Corporation, Austin, Texas, USA), which ana-
lyses data with a 5-parametric logistic weighted curve fit,
was used to determine cytokine and MMP concentra-
tions. Cytokine and MMP concentrations between
groups were compared using Kruskal-Wallis test with
Dunn’s post-hoc analysis. All values are expressed as
mean ± standard error of the mean (SEM) with signifi-
cance set at P < 0.05.
Results
ALM improves chondrocyte viability
The viability of chondro-MSC treated with ALM solu-
tion for 1 h was significantly greater than cultures
exposed to normal saline (96.2 ± 7.9% v 75.6 ± 7.3%, P
= .045, Fig. 2a). In contrast, chondrotoxicity was demon-
strated by significantly reduced viability in cultures
exposed to ALM solution where lidocaine concentra-
tions were increased to 30mM (44.5 ± 4.6%) or 60mM
(5.8 ± 3.1%, P < 0.001, Fig. 2b). There was no difference
in the viability of ALM-treated chondro-MSC between 1
and 4 h of exposure (85.4 ± 5.6% v 74 ± 15.2%. P = .214,
Fig. 2c).
Exposure of chondro-MSC to adenosine alone (1
mM) or lidocaine alone (3 mM) resulted in viability
that was comparable to cultures exposed to saline ve-
hicle (saline, 86.9 ± 4.9%; adenosine, 87.6 ± 5.6%; lido-
caine 94.5 ± 7.1%; P = .93). In separate experiments,
viability was significantly higher in chondro-MSC cul-
tures exposed to normal saline with Mg2+ compared
to saline alone (108 ± 6.8% v 79.3 ± 7.6%, P = .043, Fig.
2e). Viability was comparable between Mg2-supple-
mented saline and ALM-treated chondro-MSC
cultures (108 ± 6.8% v 97.6 ± 9.4%, Fig. 2e).
Chondroprotection has previously been demon-
strated in response to increased osmolarity in bovine
cartilage explant cultures (480 mOsm, ~ 1.3% saline)
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(Amin et al. 2010). To investigate whether chondro-
cyte viability was affected by saline solution osmolar-
ity in the current study, chondro-MSC were cultured
in the presence of 0.9% or 1.3% saline only, ALM in
0.9% saline or ALM in 1.3% saline. No significant dif-
ferences were observed in the viability of
chondro-MSC exposed to either 0.9% or 1.3% saline
(87.4 ± 7.3% v 78.6 ± 11.7%, P = .894). Similarly, the
viability of chondro-MSC exposed to ALM in 0.9%
saline was comparable to cultures exposed to ALM in
1.3% saline (P = .667, Fig. 2d).
Effects of ALM and TXA on chondrocyte viability and
inflammatory response
No significant differences were observed in the viability
of chondro-MSC exposed to ALM or TXA for 1 h (80 ±
5.4% v 57.3 ± 16.2%, P = .47) or 4 h (60.1 ± 17.3% v 34.6
± 12.3%, P = .49, Fig. 2f ).
Cell-free culture supernatants were assessed for inflam-
matory cytokine and chemokines and MMP concentra-
tions following exposure to ALM or TXA for 1 h (Fig. 3).
Levels of IL-1β, TNF-α and MMP-12 were below the limit
of detection for each treatment group, despite measurable
Fig. 2 Effect of saline, ALM and TXA solutions on chondro-MSC viability, where cell viability is defined as the mean absorbance of treated (saline, ALM,
TXA) cells normalised to the mean absorbance of untreated (culture media only) cells. a Compared to 0.9% saline, viability was significantly greater in
cultures exposed to ALM solution for 1 h (P = .045, n = 13). b Increasing lidocaine concentrations within the ALM preparation to 30mM (AL30M) and
60mM (AL60M) resulted in significantly reduced viability (P < .001, n = 6, # compared to saline; ^ compared to ALM). c There were no significant
differences in chondrocyte viability at 1 and 4 h exposure of chondrocytes to ALM solution. d No significant differences were observed between 0.9%
and 1.3% saline (n = 6). e Compared to normal saline (0.9%), addition of Mg2+ significantly improved cell viability (P = .043, n = 11). f No significant
differences were observed in the viability of cultures exposed to ALM solution or TXA for 1 (P = .47) or 4 h (P = .49; n = 5). Data is expressed as mean ±
S.E.M. ALM, adenosine, lidocaine, and magnesium; MgSO4, magnesium sulphate; MSC, mesenchymal stem cells; TXA, tranexamic acid
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levels in rhIL-1β-treated chondro-MSC cultures (IL-1β
3.0 ± 0.2 pg/ml, TNF-α 2.8 ± 0.5 pg/ml, MMP-12, 340 ±
71.2 pg/ml). In contrast, secretion of IL-8 was significantly
increased in chondro-MSC cultures exposed to TXA (P
= .044) compared to untreated (culture media only) cells
(Fig. 3a). Levels of MMP-3 and MMP-13 were comparable
for between treatment groups, however greater variability
was observed in the concentrations of these MMPs in cul-
tures exposed to TXA (Fig. 3b).
Discussion
We report the absence of cytotoxic and inflammatory
responses following short-term, in vitro exposure of human
chondro-MSC to ALM solution. ALM solution is an emer-
ging small-volume therapy containing a combination of
adenosine, lidocaine and magnesium (Dobson and Letson
2016). At high concentrations, ALM solution arrests the
heart and is currently in clinical use as a method for polar-
izing cardioplegia (Djabir et al. 2013). At 10-fold lower
‘non-arrest’ concentrations, ALM solution has been shown
to correct coagulopathy, improve cardiac function, and
reduce immune-inflammatory activation in response to
sterile surgery and trauma in preclinical models (Granfeldt
et al. 2014, Dobson et al. 2015, Letson and Dobson 2015,
Davenport et al. 2017, Letson and Dobson 2017a, b, Letson
and Dobson 2018a, b).
ALM appears to be safe at low lidocaine concentrations
The present study found that ALM solution (3 mM or
0.08% lidocaine) significantly improved chondrocyte via-
bility by 30% compared to normal saline. No benefit was
found using a higher 1.3% hypertonic salt solution,
which some groups have reported is more chondropro-
tective than normal saline (Amin et al. 2010). Consistent
with the findings of previous studies using human chon-
drocytes (Karpie and Chu 2007, Baker et al. 2011), lido-
caine at higher concentrations (30 and 60mM) was
toxic to chondro-MSC in the current study, with cell
viability decreasing by 65% and 95%, respectively. The
mechanisms for lidocaine toxicity at 1% (37 mM) or 2%
(74 mM) concentrations, and other local anesthetics (e.g.
bupivacaine, ropivacaine, mepivacaine), appear to be
associated with impairment of chondrocyte metabolism,
which leads to cell death (Kreuz et al. 2018). Dragoo and
colleagues (Dragoo et al. 2012) also showed that 1% lido-
caine in human monolayer chondrocyte cultures was
associated a reduction of extracellular matrix molecules,
glycosaminoglycan, and collagen content compared to
controls after 3 h. Interestingly, Baker et al. (2011)
showed that lidocaine toxicity could be attenuated with
the addition of magnesium. In the present study, we
found the addition of magnesium sulphate to normal
saline led to 10% higher cell viability. The significance of
using ALM solution compared to Mg2+ alone will be
discussed in Potential Clinical Relevance section (see
below).
Chondrocyte viability comparable for ALM and TXA
solution
Using a clinically relevant, intra-articular dose of TXA
(100 mg/ml; Ishida et al. 2011, Tuttle et al. 2014), our
study found no significant difference between normal
Fig. 3 Concentration of (a) IL-8, (b) MMP-3, (c) MMP-12 and (d) MMP-13 in chondro-MSC cultures left untreated (culture media only) or exposed
to 0.9% saline, ALM, TXA or recombinant human IL-1β. Data is expressed as mean ± S.E.M. *P < 0.05 compared to no treatment. ALM, adenosine,
lidocaine, and magnesium; IL, interleukin; MMP, matrix metalloproteinase; MSC, mesenchymal stem cells; TXA, tranexamic acid
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saline, ALM and TXA after 1 h exposure, although mean
chondro-MSC viability in TXA-exposed cultures was
reduced by 15% and 29% compared to normal saline and
ALM solution, respectively. Parker et al. (2018) recently
demonstrated significant dose-response chondrotoxicity
of TXA toward human chondrocytes using lower con-
centrations of TXA (40mg/ml), with a 58% loss of
viability in monolayers, and approximately 30% decrease
in hydrogel-encapsulated 3D human chondrocyte
cultures following 3 h exposure. Parker et al. (2018) and
more recently, Ambra et al. (2017) recommended that
intraarticular administration of TXA in orthopaedic
surgery may be safe at TXA concentrations below 20
mg/ml (Parker et al. 2018). Notwithstanding these stud-
ies, standardised protocols for intra-articular use of TXA
are lacking and debate continues regarding potential det-
rimental effects following its use in arthroscopy and
other orthopaedic procedures where native articular
cartilage remains (Jang et al. 2014, Goyal et al. 2017, Fill-
ingham et al. 2018, Grant et al. 2018, Moskal and Capps
2018, Parker et al. 2018). Further in vivo studies are re-
quired to evaluate potential underlying dose-dependent
mechanisms of TXA chondrotoxicity.
Absence of inflammatory activation of chondrocytes
exposed to ALM
Another interesting finding in our study was that ALM
solution did not activate secretion of inflammatory media-
tors known to be involved in cartilage breakdown and
joint deterioration (Chen et al. 2014, Pap and Korb-Pap
2015, Takahashi et al. 2015, Minguzzi et al. 2018) from hu-
man chondro-MSC cultures, with responses comparable
to those exposed to normal saline (Fig. 3). No statistically
significant difference was observed in inflammatory medi-
ator concentrations between cultures exposed to either sa-
line, ALM or TXA, although levels of IL-8 were
significantly higher in chondro-MSC cultures treated with
TXA compared to untreated cultures. IL-8 is expressed at
increased levels in human osteoarthritic chondrocytes
(Takahashi et al. 2015, Minguzzi et al. 2018) and is associ-
ated with: 1) production of IL-1β, IL-6, and TNF-α, 2) the
induction of chondrocyte hypertrophy and differentiation,
2) the release of MMP-13, and 3) neutrophil-mediated in-
flammation and cartilage breakdown from generation of
reactive oxygen metabolites (Lotz et al. 1992, Takahashi et
al. 2015). It is noteworthy that TXA administration in pa-
tients undergoing TKA was recently demonstrated to lead
to significant increases in plasma inflammatory cytokines
during and after surgery (Grant et al. 2018).
Potential clinical relevance
During orthopaedic surgical procedures, surgery-induced
damage within joint tissues can activate chondrocytes in
articular cartilage (Schulze-Tanzil 2009, Dobson 2015).
Chondrocyte activation leads to increased production of
pro-inflammatory cytokines such as IL-1β and TNF-α
which, in the absence of homeostatic regulation, drive
an inflammatory cascade that promotes upregulation of
cartilage-degrading proteinases and chondrocyte apop-
tosis (Schulze-Tanzil 2009, Pap and Korb-Pap 2015,
Minguzzi et al. 2018). Strategies to reduce secondary in-
jury progression are actively being sought to improve
regulation of the postoperative healing process and pa-
tient outcomes. Small-volume bolus and infusion of
ALM solution has been shown to improve survival and
prevent secondary injury progression in a number of dif-
ferent trauma states in small and large animal models of
hemorrhagic shock (Granfeldt et al. 2014, Dobson and
Letson 2016, Letson and Dobson 2017a, b), cardiac ar-
rest (Djabir et al. 2013), polymicrobial sepsis (Griffin et
al. 2014, Griffin et al. 2016), abdominal surgery (Daven-
port et al. 2017), and more recently traumatic brain in-
jury (Letson and Dobson 2018a, b). The addition of
magnesium to normal saline was found to increase
chondro-MSC viability in the current study and is con-
sistent with in vitro chondroprotective properties de-
scribed by others (Baker et al. 2011). The analgesic
properties of magnesium may be due to its ability to
block NMDA receptors and potentially through inhibi-
tory effects on calcium and potassium channels, thus
augmenting neural transmission (Srebro et al. 2016).
Magnesium has been evaluated as an alternative
intra-articular analgesic in arthroscopic knee surgery
conferring better pain relief than placebo (Bondok and
Abd El-Hady 2006), and showing a synergistic effect
when combined with bupivacaine (Devi et al. 2018). Ad-
enosine has also been shown to play a key role in cartil-
age homeostasis (Mediero and Cronstein et al. 2013).
Importantly, preclinical studies have shown the
whole-body protective benefits of ALM solution can-
not be achieved using each drug individually (Dobson
and Letson 2016). It is envisaged that an ALM infu-
sion or intra-articular bolus may benefit patients
undergoing orthopaedic interventions, and other
major surgery, by reducing surgical stress, preventing
bleeding and promoting a more permissive environ-
ment that enhances tissue healing following major
surgery (Dobson 2015, Davenport et al. 2017). The
potential clinical application of ALM solution in
orthopaedic surgery as a novel strategy for protecting
native articular cartilage and improving patient out-
comes is currently being investigated.
Limitations
A potential limitation of the present study may be the
use of chondrogenically differentiated human bone mar-
row derived MSC, rather than human primary chondro-
cytes or cartilage explants. However, Kalamegam et al.
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(2016) have shown chondrogenic differentiation of hu-
man bone marrow MSC using similar methods and
culture supplements, with chondrocyte-like cells acquir-
ing a polygonal morphology and increased expression of
type II collagen within 7 days of culture and continued
deposition of cartilaginous matrix over a 21-day period.
We also acknowledge that different substrate surfaces
were used for viability and cytokine assays (polystyrene)
and histology of disc cultures (porous polycarbonate
membrane), though chondrogenesis of MSC has
been demonstrated for both (Kalamegam et al. 2016,
Murdoch et al. 2009). Our findings suggest, even with
direct contact for up to 4 h, exposure to ALM solution
had no adverse effect on chondrocyte-like cells in culture.
However, in vitro studies cannot represent the complex-
ities of the joint microenvironment and it is possible that
the phenotypic responses we found in response to ALM
solution may differ in vivo. Future studies that include
more extensive investigation of inflammatory and oxida-
tive stress responses of mature articular cartilage exposed
to ALM solution in vivo are warranted and are the focus
of current research.
Conclusions
We conclude that short-term exposure of human chon-
drocyte monolayers to ALM solution improved viability
compared to saline alone. In addition, ALM did not
stimulate secretion of key inflammatory mediators or
matrix-degrading MMP that are believed to delay heal-
ing and promote secondary injury.
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